Buscar
Protagonist Therapeutics Inc
PTGXAñadir a la lista de seguimiento
136.640USD
-2.000-1.44%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
8.79BCap. mercado
PérdidaP/E TTM
Más Datos de Protagonist Therapeutics Inc Compañía
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Información de Protagonist Therapeutics Inc
Símbolo de cotizaciónPTGX
Nombre de la empresaProtagonist Therapeutics Inc
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoPatel (Dinesh V)
Número de empleados126
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 11
Dirección7707 Gateway Blvd Ste 140
CiudadNEWARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94560-1160
Teléfono15104740170
Sitio Webhttps://www.protagonist-inc.com/
Símbolo de cotizaciónPTGX
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoPatel (Dinesh V)
Ejecutivos de Protagonist Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
287.44K
--
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
123.77K
+54.99%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
5.13K
+47.47%
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
5.13K
+47.47%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
1.93K
+54.36%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
287.44K
--
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
123.77K
+54.99%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
5.13K
+47.47%
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
5.13K
+47.47%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
1.93K
+54.36%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Protagonist Therapeutics Inc?
Los cinco principales accionistas de Protagonist Therapeutics Inc son: Dr. Dinesh V. Patel, Ph.D.
¿Cuántas instituciones poseen acciones de Protagonist Therapeutics Inc (PTGX)?
A fecha de 2026Q1, 642 instituciones poseen acciones de Protagonist Therapeutics Inc, con un valor de mercado combinado de aproximadamente 76.23M, lo que representa el 118.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3232024.00.